Pluvicto (lutetium Lu 177 VIP1963) is a radioligand therapeutic designed for intravenous administration. Radioligand therapies like Pluvicto are typically given as an injection into a vein.

For specific administration details, such as dosage, infusion rate, premedication, or post-infusion care, one would need to refer to the drug's prescribing information or consult a healthcare professional. It's also essential to consider that the exact administration procedure can depend on the clinical setting, the patient's health status, and the presence of any other medical conditions or treatments.

Patients receiving radioligand therapy usually undergo a series of safety checks before administration to ensure they are suitable candidates for the treatment. This might include blood tests, scans, and other assessments. After the infusion, patients might be monitored for a period to check for any immediate adverse reactions or complications.

Pluvicto is a type of treatment for prostate cancer patients who have already been treated with other anticancer treatments.

The drug combines a targeting compound (called a ligand, meant to bring the drug to the cancer cells) with a therapeutic radioisotope (radioactive particle meant to damage the cancer cells). This treatment focuses on prostate cancer cells that express PSMA, a specific protein on the outside of the cancer cells.

The damage that is done to the cancer cells stops their ability to replicate (reproduce, multiply) and can also trigger cancer cell death.